PDGFRB and cholangiocarcinoma: Sorafenib, a multikinase inhibitor targeting VEGFR, PDGFR, and Raf, has been extensively evaluated in clinical trials for CCA but has failed to produce significant benefits, either as monotherapy or in combination.